LakeShore Biopharma Co Ltd Ordinary Shares LSB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
-
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024
-
LakeShore Biopharma Announces Leadership Transitions
-
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
-
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition
Trading Information
- Previous Close Price
- $0.78
- Day Range
- $0.71–0.85
- 52-Week Range
- $0.35–1.12
- Bid/Ask
- $0.80 / $0.84
- Market Cap
- $159.76 Mil
- Volume/Avg
- 410,222 / 41,247
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.12
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 0
- Website
- https://www.lakeshorebio.com
Comparables
Valuation
|
Metric
|
LSB
|
06855
|
02256
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 321.46 |
Price/Book Value | 1.94 | 175.16 | 0.97 |
Price/Sales | 1.12 | 12.01 | 4.09 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LSB
|
06855
|
02256
|
|---|---|---|---|
Quick Ratio | 0.86 | 1.32 | 21.59 |
Current Ratio | 1.13 | 1.44 | 21.75 |
Interest Coverage | −9.26 | −9.05 | −10.45 |
Quick Ratio
LSB
06855
02256
Profitability
|
Metric
|
LSB
|
06855
|
02256
|
|---|---|---|---|
Return on Assets (Normalized) | −13.07% | −32.67% | 0.63% |
Return on Equity (Normalized) | −33.73% | −254.45% | 0.70% |
Return on Invested Capital (Normalized) | −15.10% | −39.49% | −3.17% |
Return on Assets
LSB
06855
02256
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mrtbynzl | Ztlpb | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jvdtvqrnh | Kmffcw | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wfzjjnfz | Mxcryjt | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Scnxyjjy | Sfydz | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Jgbfjwdd | Kqy | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Yhddcngw | Bpbd | $28.1 Bil | |||
| Moderna Inc
MRNA
| Nmrjzvmqg | Tdjt | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Bskjgnrw | Nxc | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lskfzhl | Qqnqvx | $13.4 Bil | |||
| Incyte Corp
INCY
| Vybbdjnys | Prbpyxn | $12.7 Bil |
United States